Multiple drugs

Multiple drugs Reactions 1704, p261 - 2 Jun 2018 O S Various toxicities: 10 case reports A case report originating from the centre of evaluation and information on pharmacodependence-addictovigilance of Paris described ten patients (seven men and three women), aged 25 84 years, who developed dependence to mephenesin; most of these patients were abusing mephenesin at an overdose. Four of ten patients also developed dependence to alprazolam, zolpidem, promethazine, doxylamine, codeine or bromazepam. Three of ten patients developed sleep disorder, anxiety, agitation, tremor or irritability following the withdrawal of mephenesin [routes, durations of treatments to reaction onsets and outcomes not stated, not all dosages and indication stated]. The patients had a history of depression, alcoholism, high BP, chronic obstructive pulmonary disease, fractured collarbone, capsulitis, sleep disorder, lumbar pain, childhood maltreatment, discal hernia, arthrosis, scoliosis, eating disorders, medication overuse headache, back pain or physical disability. Additionally, in six of the 10 patients, history was significant for alcoholism, overweight, gambling, illicit drugs use, alcohol abuse or cannabis use. The social history was significant for only tobacco (three patients), only alcohol (one patient) and both alcohol and tobacco (two patients). Seven of the ten patients were also receiving current medications. All the patients received mephenesin and dose was – – 1 144 gram/day for a duration of 3 months 6 years (8 patients). Six of the 10 patients were using mephenesin to seek effect such as sedation, anxiolytic, hypnotic, sensation of well-being, analgesic or anti-craving for alcohol. Thereafter, eight of the 10 patients, met the criteria for diagnostic and statistical manual of mental disorders fifth edition for substance-related and addictive disorders, while in two patients it was unknown for mephenesin. The treatment with mephenesin was discontinued in all the patients. In three of the 10 patients developed sleep disorder (n=1), anxiety, agitation, sleep disorder and tremor (n=1) and anxiety, tremor and irritability (n=1) following the withdrawal of mephenesin. In four the 10 patients multiple drug dependence was noted, of which two patients were also dependent on alprazolam, one patient on zolpidem, promethazine and doxylamine and remaining one patient on codeine and bromazepam. Author comment: "[W]e reported 10 new clinical cases of mephenesin use disorder collected between 2012 and 2017." "Four patients presented multiple drug dependence." Chevallier C, et al. Mephenesin: Is There a Progression in Cases of Substance Use Related Disorders in France?. Journal of Clinical Psychopharmacology 38: 275-277, No. 3, Jun 2018. Available from: URL: http://doi.org/10.1097/ JCP.0000000000000884 - France 803323796 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Multiple drugs

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018
Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/multiple-drugs-ZJ0z2ZUKR0
Publisher
Springer International Publishing
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-018-46904-6
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p261 - 2 Jun 2018 O S Various toxicities: 10 case reports A case report originating from the centre of evaluation and information on pharmacodependence-addictovigilance of Paris described ten patients (seven men and three women), aged 25 84 years, who developed dependence to mephenesin; most of these patients were abusing mephenesin at an overdose. Four of ten patients also developed dependence to alprazolam, zolpidem, promethazine, doxylamine, codeine or bromazepam. Three of ten patients developed sleep disorder, anxiety, agitation, tremor or irritability following the withdrawal of mephenesin [routes, durations of treatments to reaction onsets and outcomes not stated, not all dosages and indication stated]. The patients had a history of depression, alcoholism, high BP, chronic obstructive pulmonary disease, fractured collarbone, capsulitis, sleep disorder, lumbar pain, childhood maltreatment, discal hernia, arthrosis, scoliosis, eating disorders, medication overuse headache, back pain or physical disability. Additionally, in six of the 10 patients, history was significant for alcoholism, overweight, gambling, illicit drugs use, alcohol abuse or cannabis use. The social history was significant for only tobacco (three patients), only alcohol (one patient) and both alcohol and tobacco (two patients). Seven of the ten patients were also receiving current medications. All the patients received mephenesin and dose was – – 1 144 gram/day for a duration of 3 months 6 years (8 patients). Six of the 10 patients were using mephenesin to seek effect such as sedation, anxiolytic, hypnotic, sensation of well-being, analgesic or anti-craving for alcohol. Thereafter, eight of the 10 patients, met the criteria for diagnostic and statistical manual of mental disorders fifth edition for substance-related and addictive disorders, while in two patients it was unknown for mephenesin. The treatment with mephenesin was discontinued in all the patients. In three of the 10 patients developed sleep disorder (n=1), anxiety, agitation, sleep disorder and tremor (n=1) and anxiety, tremor and irritability (n=1) following the withdrawal of mephenesin. In four the 10 patients multiple drug dependence was noted, of which two patients were also dependent on alprazolam, one patient on zolpidem, promethazine and doxylamine and remaining one patient on codeine and bromazepam. Author comment: "[W]e reported 10 new clinical cases of mephenesin use disorder collected between 2012 and 2017." "Four patients presented multiple drug dependence." Chevallier C, et al. Mephenesin: Is There a Progression in Cases of Substance Use Related Disorders in France?. Journal of Clinical Psychopharmacology 38: 275-277, No. 3, Jun 2018. Available from: URL: http://doi.org/10.1097/ JCP.0000000000000884 - France 803323796 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off